OncoMatch/Clinical Trials/NCT06696742
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Is NCT06696742 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Clostridium Butyricum Tablets and Cisplatin for bladder (urothelial, transitional cell) cancer.
Treatment: Clostridium Butyricum Tablets · Cisplatin — This study intends to explore whether the combination of Clostridium butyricum can improve the current situation of poor anti-PD1 treatment effect in patients with bladder cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Disease stage
Required: Stage T2-T4AN0M0, T3-T4
For Neoadjuvant therapy: T2-T4aN0M0 bladder patients; For Adjuvant therapy: Postoperative pathological stage T3-T4 and/or lymph node metastasis were positive.
Prior therapy
Cannot have received: systemic chemotherapy
Previously received systemic chemotherapy
Cannot have received: immunotherapy
Previously received...immunotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06696742 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T2-T4AN0M0 or T3-T4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify